The spondyloarthritides are a group of chronic systemic inflammatory joint diseases, the
main types being ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Evidence accumulating during
the last decades suggests that patients with AS or PsA carry an increased risk for cardiovascular
disease and cardiovascular death. This risk appears to be mediated by systemic inflammation over and
above classical cardiovascular risk factors. The excess cardiovascular risk in those patients has been
formally acknowledged by scientific organizations, which have called physicians’ attention to the matter.
The application by Rheumatologists of new effective anti-rheumatic treatments and treat-to-target
strategies seems to benefit patients from a cardiovascular point of view, as well. However, more data are
needed in order to verify whether anti-rheumatic treatments do have an effect on cardiovascular risk and
whether there are differences among them in this regard. Most importantly, a higher level of awareness
of the cardiovascular risk is needed among patients and healthcare providers, better tools to recognize
at-risk patients and, ultimately, commitment to address in parallel both the musculoskeletal and the cardiovascular
aspect of the disease.
Clinical phenotype clustering in cardiovascular risk patients for the identification of responsive metabotypes after red wine polyphenol intake
